Literature DB >> 22718274

Skeletal manifestations in pediatric and adult patients with Niemann Pick disease type B.

Melissa Wasserstein1, James Godbold, Margaret M McGovern.   

Abstract

INTRODUCTION: Niemann-Pick disease (NPD) due to acid sphingomyelinase deficiency is a lipid storage disease resulting from the accumulation of sphingomyelin, predominantly within cells of the monocyte-macrophage system. In contrast to other lysosomal storage disorders, skeletal involvement in NPD has not been systematically studied.
METHODS: Pediatric and adult NPD-B patients underwent medical histories and physical examinations, DEXA scans to measure bone mineral content (BMC), and bone mineral density (BMD) and computed tomography scan or MRI of the abdomen for spleen volume. Z and/or T scores were calculated for the DEXA results. For the pediatric patients adjusted mean BMC (g) and BMD (g/cm(2)) of the lumbar spine, hip, and femoral neck was compared to control subjects. For determination of the relationship between spleen volume and lumbar spine BMD Z score, linear correlation analyses were performed.
RESULTS: Lumbar spine Z scores for pediatric patients ranged from 0.061 to -4.879. Statistically significant decreases were observed for the adjusted mean BMC and BMD at the lumbar spine, hip, and femoral neck between the pediatric NPD-B cohort and control subjects. Most NPD-B adults were osteopenic or osteoporotic at one or more sites according the WHO classification of BMD. In NPD-B patients, the degree of splenomegaly was inversely correlated with lumbar spine BMD Z scores.
CONCLUSION: Skeletal involvement is a common and previously unrecognized manifestation of NPD-B. The association between splenomegaly and BMD lends further support to spleen size as an indicator of disease severity.

Entities:  

Mesh:

Year:  2012        PMID: 22718274     DOI: 10.1007/s10545-012-9503-0

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  21 in total

1.  Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease.

Authors:  Dominique P Germain; Karelle Benistan; Pierre Boutouyrie; Celine Mutschler
Journal:  Clin Genet       Date:  2005-07       Impact factor: 4.438

2.  Natural history of Type A Niemann-Pick disease: possible endpoints for therapeutic trials.

Authors:  M M McGovern; A Aron; S E Brodie; R J Desnick; M P Wasserstein
Journal:  Neurology       Date:  2006-01-24       Impact factor: 9.910

3.  Potent and selective inhibition of acid sphingomyelinase by bisphosphonates.

Authors:  Anke G Roth; Daniela Drescher; Yang Yang; Susanne Redmer; Stefan Uhlig; Christoph Arenz
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

4.  Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy.

Authors:  Patrick B Deegan; Elena Pavlova; Jane Tindall; Penelope E Stein; Philip Bearcroft; Atul Mehta; Derralynn Hughes; J Edmund Wraith; Timothy M Cox
Journal:  Medicine (Baltimore)       Date:  2011-01       Impact factor: 1.889

Review 5.  Bone complications in children with Gaucher disease.

Authors:  B Bembi; G Ciana; E Mengel; M R Terk; C Martini; R J Wenstrup
Journal:  Br J Radiol       Date:  2002       Impact factor: 3.039

6.  Bone mineral density in children and adolescents with neurofibromatosis type 1.

Authors:  David A Stevenson; Laurie J Moyer-Mileur; Mary Murray; Hillarie Slater; Xiaoming Sheng; John C Carey; Bukhosi Dube; David H Viskochil
Journal:  J Pediatr       Date:  2007-01       Impact factor: 4.406

7.  A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B.

Authors:  Margaret M McGovern; Melissa P Wasserstein; Roberto Giugliani; Bruno Bembi; Marie T Vanier; Eugen Mengel; Scott E Brodie; David Mendelson; Gwen Skloot; Robert J Desnick; Noriko Kuriyama; Gerald F Cox
Journal:  Pediatrics       Date:  2008-07-14       Impact factor: 7.124

8.  Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density.

Authors:  Henriette Mersebach; Jan-Ove Johansson; Ase Krogh Rasmussen; Bengt-Ake Bengtsson; Kirsten Rosenberg; Lis Hasholt; Sven Asger Sørensen; Søren Schwartz Sørensen; Ulla Feldt-Rasmussen
Journal:  Genet Med       Date:  2007-12       Impact factor: 8.822

9.  Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy.

Authors:  Richard J Wenstrup; Laurie Bailey; Gregory A Grabowski; Jay Moskovitz; Alan E Oestreich; Wei Wu; Shumei Sun
Journal:  Blood       Date:  2004-03-09       Impact factor: 22.113

10.  Roles of specific cytokines in bone remodeling and hematopoiesis in Gaucher disease.

Authors:  Makoto Yoshino; Yoriko Watanabe; Yasuyuki Tokunaga; Eimiei Harada; Chieko Fujii; Sanae Numata; Masaru Harada; Asako Tajima; Hiroyuki Ida
Journal:  Pediatr Int       Date:  2007-12       Impact factor: 1.524

View more
  13 in total

Review 1.  Pulmonary Involvement in Niemann-Pick Disease: A State-of-the-Art Review.

Authors:  Felipe Mussi von Ranke; Heloisa Maria Pereira Freitas; Alexandre Dias Mançano; Rosana Souza Rodrigues; Bruno Hochhegger; Dante Escuissato; Cesar Augusto Araujo Neto; Thiago Krieger Bento da Silva; Edson Marchiori
Journal:  Lung       Date:  2016-05-10       Impact factor: 2.584

2.  Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency.

Authors:  Melissa P Wasserstein; Simon A Jones; Handrean Soran; George A Diaz; Natalie Lippa; Beth L Thurberg; Kerry Culm-Merdek; Elias Shamiyeh; Haig Inguilizian; Gerald F Cox; Ana Cristina Puga
Journal:  Mol Genet Metab       Date:  2015-05-30       Impact factor: 4.797

3.  Pitfalls in Diagnosing Neuraminidase Deficiency: Psychosomatics and Normal Sialic Acid Excretion.

Authors:  Imre F Schene; Viera Kalinina Ayuso; Monique de Sain-van der Velden; Koen L I van Gassen; Inge Cuppen; Peter M van Hasselt; Gepke Visser
Journal:  JIMD Rep       Date:  2015-07-05

Review 4.  Types A and B Niemann-Pick disease.

Authors:  Edward H Schuchman; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2016-12-16       Impact factor: 4.797

5.  Bone mineral density in patients with mucopolysaccharidosis type III.

Authors:  Banu Guzel Nur; Hakan Nur; Ercan Mihci
Journal:  J Bone Miner Metab       Date:  2016-05-18       Impact factor: 2.626

6.  Evaluation of bone health in patients with mucopolysaccharidosis.

Authors:  Deniz Kor; Fatma Derya Bulut; Sebile Kılavuz; Berna Şeker Yılmaz; Burcu Köşeci; Esra Kara; Ömer Kaya; Sibel Başaran; Gülşah Seydaoğlu; Neslihan Önenli Mungan
Journal:  J Bone Miner Metab       Date:  2022-01-23       Impact factor: 2.626

Review 7.  Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency.

Authors:  Margaret M McGovern; Carlo Dionisi-Vici; Roberto Giugliani; Paul Hwu; Olivier Lidove; Zoltan Lukacs; Karl Eugen Mengel; Pramod K Mistry; Edward H Schuchman; Melissa P Wasserstein
Journal:  Genet Med       Date:  2017-04-13       Impact factor: 8.822

Review 8.  Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD).

Authors:  Margaret M McGovern; Ruzan Avetisyan; Bernd-Jan Sanson; Olivier Lidove
Journal:  Orphanet J Rare Dis       Date:  2017-02-23       Impact factor: 4.123

Review 9.  Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD).

Authors:  Melissa Wasserstein; Carlo Dionisi-Vici; Roberto Giugliani; Wuh-Liang Hwu; Olivier Lidove; Zoltan Lukacs; Eugen Mengel; Pramod K Mistry; Edward H Schuchman; Margaret McGovern
Journal:  Mol Genet Metab       Date:  2018-11-29       Impact factor: 4.797

10.  Assessment of bone mineral density by dual energy x-ray absorptiometry in patients with mucopolysaccharidoses.

Authors:  Hsiang-Yu Lin; Shou-Chuan Shih; Chih-Kuang Chuang; Ming-Ren Chen; Dau-Ming Niu; Shuan-Pei Lin
Journal:  Orphanet J Rare Dis       Date:  2013-05-11       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.